Sublingual Semaglutide (generic Ozempic®) now available! Get Started
Dashboard
Formulas

Semaglutide 0.75 mg/mL Sublingual Suspension

The Semaglutide 0.75 mg/mL Sublingual Suspension is a specialized liquid medication formulated for sublingual administration. This advanced suspension utilizes SubMagna™ SL HMW base, an anhydrous, self-emulsifying vehicle that enhances the permeation of semaglutide.

Designed for ease of use, the suspension is delivered via oral syringe that allow for precise dosing. The sublingual route of administration also bypasses gastrointestinal factors that can affect the bioavailability of the drug, potentially offering a more consistent therapeutic effect.

Patients often include semaglutide in their regimens for managing type 2 diabetes, obesity, and weight.

This formulation is NOT the injectable version, and we do not guarantee efficacy. Results may vary.

Want a different strength?
Click the Text Us button below.
To prescribe, you must be a verified prescriber.
To prescribe, you must be in a state where we hold an active out-of-state pharmacy license.
Starting at
$210 per Month
Must be E-Prescribed
Get Started
Generate LeafletShow Leaflet
This medication requires a prescription from your doctor
Are you a prescriber? Sign Up
Trusted by 60,357 patients to date.
A group of faces of our past satisfied patients.
A svg symbol of a mortar and pestle with ingredients going in.
Custom made in our compounding labs.
Sliders that show the customization of ingredients.
Personalized treatment for better results.
User with a gear showing the personalization of the formulation.
All strengths and ingredients are tailored to your needs.
This medication is not available at retail pharmacies. It is compounded, and may be more effective at treating you or your patient.
Oral Syringe
65dcecf251313fe82e4e76d7
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Loading icon rotating.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Dosing Calculator

Get general dosing information for a patient by using this calculator.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Loading icon rotating.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Formula Information

A small arrow pointing down

Our Semaglutide 0.75 mg/mL Sublingual Suspension is a meticulously crafted liquid formulation, specifically designed for sublingual administration. This advanced delivery system is delivered via an oral syringe, which allow for precise dosing and ease of use. The formulation is particularly suitable for patients who require smaller doses or for those who may face challenges swallowing traditional solid dosage forms, such as tablets or capsules, including pediatric patients.

The active pharmaceutical ingredient (API) in this formulation, Semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily used in the management of type 2 diabetes mellitus. Semaglutide works by enhancing the secretion of insulin, which lowers blood glucose levels, and by suppressing the release of glucagon, which in turn reduces hepatic glucose production. Additionally, it slows gastric emptying and reduces appetite and food intake. These actions collectively contribute to better glycemic control and may also support weight loss in patients with type 2 diabetes.

The cutting-edge SubMagna™ SL HMW base used in our formulation is specifically engineered to deliver drugs, including those with high molecular weights (HMWs). This anhydrous, self-emulsifying, and permeation-enhancing sublingual suspension vehicle forms an emulsion upon contact with saliva, which significantly improves the solubility and dispersibility of the API. The unique mucoadhesive properties of SubMagna™ SL HMW ensure prolonged contact with mucosal tissues, potentially enhancing the absorption of Semaglutide. This is particularly beneficial for molecules with HMWs that typically face challenges in transmucosal delivery.

By utilizing the sublingual route, our formulation offers an alternative pathway for drug administration that bypasses the gastrointestinal tract. This can be advantageous in avoiding the impact of gastrointestinal factors on the bioavailability of the API, such as degradation by stomach acid or first-pass metabolism in the liver. Moreover, the anhydrous nature of the SubMagna™ SL HMW base may extend the beyond-use-dates (BUDs) of the formulation, potentially offering greater stability and shelf-life compared to aqueous-based formulations.

For patients and prescribers considering our Semaglutide 0.75 mg/mL Sublingual Suspension, it represents a novel and efficient option for managing type 2 diabetes, with the added benefits of a user-friendly delivery system and the potential for improved pharmacokinetics. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of expert compounding pharmacists is dedicated to providing comprehensive support and guidance to ensure optimal therapeutic outcomes for our patients.

Drug Interactions

A small arrow pointing down

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus to improve glycemic control in conjunction with diet and exercise. It functions by enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. When considering the sublingual suspension formulation of semaglutide, it is important to be aware of potential drug interactions that may affect its efficacy and safety.

One significant interaction is with drugs that affect gastrointestinal motility, as the mechanism of action of semaglutide includes delaying gastric emptying. Medications such as prokinetic agents could potentially diminish the effectiveness of semaglutide by accelerating gastric emptying, thereby affecting the absorption of the medication. Conversely, drugs that slow gastric emptying could enhance the glucose-lowering effect of semaglutide and increase the risk of gastrointestinal side effects such as nausea and vomiting.

Additionally, semaglutide may interact with other antidiabetic medications, leading to an increased risk of hypoglycemia. When used in combination with insulin or insulin secretagogues such as sulfonylureas, patients may require a lower dose of these medications to mitigate the risk of hypoglycemia. It is crucial to monitor blood glucose levels closely when initiating or adjusting semaglutide therapy in combination with other antidiabetic drugs.

Patients taking medications that have a narrow therapeutic index and are metabolized by cytochrome P450 enzymes should be monitored closely when starting semaglutide. Although semaglutide is not metabolized by cytochrome P450 enzymes and does not directly affect their activity, changes in gastric emptying may alter the absorption and concentration of these medications. Examples include warfarin and other oral anticoagulants, where fluctuations in drug levels could have significant clinical consequences.

It is also important to consider the impact of the SubMagna SL HMW base on drug interactions. The permeation-enhancing and mucoadhesive properties of the base may affect the absorption of concurrently administered sublingual or buccal medications. Patients should be advised to separate the administration of semaglutide from other sublingual or buccal medications to prevent altered absorption.

Lastly, patients should be counseled on the potential for interactions with over-the-counter medications, herbal supplements, and nutraceuticals, as these can also affect blood glucose levels and the action of semaglutide. For example, products containing corticosteroids or sympathomimetics may counteract the glucose-lowering effect of semaglutide and necessitate adjustments in dosing.

Due to the complexity of drug interactions and individual patient factors, it is recommended that prescribers closely monitor patients and adjust therapy as needed. Pharmacists can provide valuable guidance on the timing of administration and potential interactions with other medications. If you have any questions or require further information regarding the use of semaglutide sublingual suspension, please reach out to us at Bayview Pharmacy for personalized support and advice.

How Does it Work

A small arrow pointing down

Our Semaglutide 0.75 mg/mL Sublingual Suspension is a cutting-edge formulation designed to treat patients with type 2 diabetes by improving glycemic control. This liquid formulation is dispensed via an oral syringe, allowing for precise and controlled administration. The sublingual route, where the medication is placed under the tongue, is particularly beneficial for patients who may have difficulty swallowing tablets or capsules, or for those who require smaller doses that need to be measured accurately.

The base of our formulation, SubMagna™ SL HMW, is specifically designed to deliver a wide range of drugs, including those with high molecular weights (HMW) like Semaglutide. When a dose of the suspension is administered under the tongue, it encounters saliva and forms an emulsion. This process improves the solubility and dispersibility of the active pharmaceutical ingredient (API), in this case, Semaglutide.

Furthermore, the permeation-enhancing and mucoadhesive properties of SubMagna™ SL HMW are crucial for the delivery of Semaglutide. These properties help to transport the molecule into the mucosal tissues beneath the tongue, ensuring that the drug is absorbed more efficiently. The mucoadhesive nature also prolongs the contact time between the drug and the mucosal tissues, potentially increasing the absorption of Semaglutide into the bloodstream. This is particularly important for a drug like Semaglutide, which has a high molecular weight and may otherwise have limited absorption through traditional oral routes.

By bypassing the gastrointestinal tract, the sublingual administration of Semaglutide with our SubMagna™ SL HMW base can circumvent factors that typically influence the bioavailability of APIs. This means that the drug can avoid degradation by stomach acid and enzymes, as well as bypass first-pass metabolism in the liver, which can significantly reduce the amount of drug that reaches systemic circulation when taken orally.

The anhydrous nature of the SubMagna™ SL HMW base also contributes to the stability of the formulation, offering the potential for longer beyond-use-dates (BUDs). This is beneficial for both patients and prescribers.

In summary, our Semaglutide 0.75 mg/mL Sublingual Suspension provides an innovative way to manage type 2 diabetes. The unique properties of the SubMagna™ SL HMW base, combined with the sublingual route of administration, offer a promising alternative for patients requiring precise dosing and those who may not tolerate or prefer not to take oral tablets or capsules. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy.

Other Uses

A small arrow pointing down

While the primary indication for Semaglutide 0.75 mg/mL Sublingual Suspension is the management of type 2 diabetes mellitus, the unique properties of the SubMagna™ SL HMW base may allow for other potential uses. The sublingual route of administration bypasses the gastrointestinal tract, which can be particularly beneficial for patients with gastrointestinal disorders that affect the absorption of oral medications. Additionally, this route can be advantageous for drugs that undergo significant first-pass metabolism, potentially allowing for a reduction in dose and associated side effects.

Given the permeation-enhancing and mucoadhesive characteristics of the SubMagna™ SL HMW base, this formulation could be explored for the delivery of other high molecular weight (HMW) peptides or proteins that require enhanced absorption into the systemic circulation. This might include hormones, certain biologics, or other peptide-based therapies that traditionally have poor oral bioavailability. The anhydrous nature of the base also suggests a potential for use with APIs that are sensitive to hydrolysis, providing a more stable environment that could extend the beyond-use date of the formulation.

Furthermore, the sublingual suspension could be considered for use in pediatric or geriatric populations, or in patients with dysphagia or other swallowing difficulties, who may benefit from a liquid formulation that does not require swallowing a pill. The oral syringe allows for precise dosing, which is particularly important when administering potent medications where small variations in dose can have significant clinical effects.

It is important to note that any alternative uses of Semaglutide 0.75 mg/mL Sublingual Suspension would require thorough investigation to establish efficacy, safety, and dosing guidelines. Prescribers considering this formulation for off-label uses should do so based on a careful assessment of the individual patient's needs and in accordance with regulatory guidelines. Patients should be counseled on the proper administration technique for sublingual suspensions to ensure optimal absorption and therapeutic effect.

For more detailed information on the potential applications of this formulation or to discuss specific patient needs, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive support and guidance to both patients and healthcare providers.

Frequently Asked Questions

A small arrow pointing down

What is Semaglutide 0.75 mg/mL Sublingual Suspension?

Semaglutide 0.75 mg/mL Sublingual Suspension is a liquid medication formulated for sublingual administration. It is delivered via an oral syringe for precise dosing and is designed to be dropped directly under the tongue for absorption through the mucosal tissues.

How do I use the Semaglutide Sublingual Suspension?

To use the suspension, simply empty the oral syringe under your tongue and hold it there for the recommended amount of time before swallowing. This allows the medication to be absorbed directly into your bloodstream through the tissues under your tongue.

What is SubMagna™ SL HMW base?

SubMagna™ SL HMW is an advanced sublingual suspension vehicle that is designed to deliver a wide range of drugs, including those with high molecular weights. It is anhydrous, self-emulsifying, and enhances permeation, which helps to improve the solubility and absorption of active pharmaceutical ingredients (APIs).

Why is sublingual administration beneficial for Semaglutide?

Sublingual administration of Semaglutide is beneficial because it bypasses the gastrointestinal tract, which can affect the bioavailability of the medication. This route also allows for quicker absorption into the bloodstream and can be more convenient for patients who have difficulty swallowing pills.

What are the advantages of SubMagna™ SL HMW base for sublingual delivery?

The SubMagna™ SL HMW base offers several advantages for sublingual delivery, including its ability to form an emulsion with saliva, which improves drug solubility and dispersibility. Its permeation-enhancing and mucoadhesive properties also help to increase the absorption of drugs into mucosal tissues and extend contact time.

Can Semaglutide Sublingual Suspension be used by pediatric patients?

Yes, the Semaglutide Sublingual Suspension is suitable for pediatric patients, especially those who have difficulty swallowing tablets or capsules. However, it is important to consult a healthcare provider for the appropriate dosing and administration for children.

How should I store the Semaglutide Sublingual Suspension?

The suspension should be stored according to the instructions provided by the pharmacy or manufacturer. Typically, it should be kept in a cool, dry place away from direct sunlight and out of reach of children.

What should I do if I miss a dose of Semaglutide Sublingual Suspension?

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

Are there any side effects associated with Semaglutide Sublingual Suspension?

As with any medication, there may be side effects. Common side effects include nausea, vomiting, diarrhea, and abdominal pain. If you experience any severe side effects or signs of an allergic reaction, seek medical attention immediately.

How long can I use the Semaglutide Sublingual Suspension after opening?

The beyond-use date (BUD) of the suspension will be provided by the pharmacy. The anhydrous formulation of SubMagna™ SL HMW base may offer the potential for longer BUDs, but it is important to adhere to the expiration date and storage instructions.

Related Formulas

Related Products
Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

No compounded medications are reviewed by the FDA for safety or efficacy.